- Lesterhuis W. Joost, Haanen John B. A. G., Punt Cornelis J. A. Cancer immunotherapy--revisited Nature reviews. Drug discovery 2011;10 (8):591-600 [PubMed]
- Simkens Lieke H. J., van Tinteren Harm, May Anne, ten Tije Albert J., Creemers Geert-Jan M., Loosveld Olaf J. L., de Jongh Felix E., Erdkamp Frans L. G., Erjavec Zoran, van der Torren Adelheid M. E., Tol Jolien, Braun Hans J. J., Nieboer Peter, van der Hoeven Jacobus J. M., Haasjes Janny G., Jansen Rob L. H., Wals Jaap, Cats Annemieke, Derleyn Veerle A., Honkoop Aafke H., Mol Linda, Punt Cornelis J. A., Koopman Miriam Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Lancet 2015;385 (9980):1843-1852 [PubMed]
- Punt Cornelis J. A., Koopman Miriam, Vermeulen Louis From tumour heterogeneity to advances in precision treatment of colorectal cancer Nature reviews. Clinical oncology 2017;14 (4):235-246 [PubMed]
- Lesterhuis W. Joost, Punt Cornelis J. A., Hato Stanleyson V., Eleveld-Trancikova Dagmar, Jansen Bastiaan J. H., Nierkens Stefan, Schreibelt Gerty, de Boer Annemiek, van Herpen Carla M. L., Kaanders Johannes H., van Krieken Johan H. J. M., Adema Gosse J., Figdor Carl G., de Vries I. Jolanda M. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice Journal of clinical investigation 2011;121 (8):3100-3108 [PubMed]
- Venderbosch Sabine, Nagtegaal Iris D., Maughan Tim S., Smith Christopher G., Cheadle Jeremy P., Fisher David, Kaplan Richard, Quirke Philip, Seymour Matthew T., Richman Susan D., Meijer Gerrit A., Ylstra Bauke, Heideman Danielle A. M., de Haan Anton F. J., Punt Cornelis J. A., Koopman Miriam Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies Clinical cancer research 2014;20 (20):5322-5330 [PubMed]
Professor Punt received his M.D. degree at the Free University of Amsterdam 1980, and was trained as an internist and medical oncologist in the University Medical Centre Utrecht and the Daniel den Hoed Cancer Centre Rotterdam, respectively. He received his Ph.D. on Protein tyrosine kinases in hematopoietic cells at the University Hospital Utrecht in 1991, and was a visiting scientist at the Laboratory of Immunology, Arizona Cancer Center, University of Arizona, Tucson U.S.A. in 1991-1992. From 1989 – 2011 he had several positions at the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, such as Professor in Experimental Gastrointestinal Oncology, Chairman of the Department of Medical Oncology, and Scientific Director of the Institute of Oncology. Since 2011 he is Professor in Medical Oncology, and Chairman of the Department of Medical Oncology, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. In 2013 he became the chairman of the AMC Oncology Centre. His areas of expertise concerns gastrointestinal cancer, with emphasis on colorectal cancer, and tumor immunology. He has held many (inter)national positions, among which the following. Since 2002 he is the Chairman of the Dutch Colorectal Cancer Group (DCCG), principal investigator of DCCG CAIRO studies. Since 2002 he is the chairman of the biannual European Multidisciplinary Colordectal Cancer Congress (EMCCC). In 2009 he was the scientific chairman of the Colorectal Cancer track of the ESMO/ECCO meeting. Since 2016 he is the chairman of the scientific committee of the Dutch Colorectal Cancer Registry (PLCRC). From 2008-2014 he was a member of the Scientific Council of the Dutch Cancer Foundation (KWF), and from 1999-2014 he was associate editor of Annals of Oncology. In 2015 he received the Hamilton Fairley Award of the European Society of Medical Oncology (ESMO) for internationally recognised outstanding achievements in cancer science and clinical/translational research.
Prof. MD PhD C.J.A. Punt (Clinical and translational research in gastrointestinal cancer, with focus on colorectal cancer)
Clinical research concerns the development and conduct of clinical trials in patients with gastrointestinal cancer, with focus on colorectal cancer, with improvement of clinical outcome and quality of life as main objectives. Secondary outcomes include quality of care and health economics. Translational research concerns the development and validation of prognostic and predictive markers in blood and tumor tissues, with clinical trial participants as main source. These studies are performed in multidisciplinary collaboration, which involves the departments of Pathology, LEXOR, Surgery, Radiology, Radiotherapy, Clinical Pharmacology and Gastroenterology within the AMC and other Academic Centres.
L. ter Hofstede-Ruiter
E.H. van Daalen
- Amgen BV
- BAYER B.V.
- Bayer AG
- Covance International Holdings B.V.
- EORTC IASBL/Quality of Life Group
- Exelixis, Inc.
- Genmab A/S
- IQVIA RDS Netherlands B.V.
- ITM Solucin GmbH
- Ipsen Farmaceutica B.V.
- KWF Kankerbestrijding
- Leiden University Medical Center
- Merck Sharp & Dohme BV
- PAREXEL International (IRL) Limited
- PPD Global Ltd
- PPD Netherlands BV
- Pharmaceutical Research Associates Group B.V.
- Research Drive BV
- Roche Nederland B.V.
- SIRTeX Technology Pty Ltd.
- Stichting Sacha Swarttouw-Hijmans
- Syneos Health UK Limited
- TESARO, inc.
- UMC St. Radboud
- Universitatsklinikum Magdeburg A.o.R., Medical Faculty